to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Vokes, Everett E.
One or more keywords matched the following items that are connected to
Vokes, Everett E.
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Protein kinase C beta in malignant pleural mesothelioma.
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Ethnic differences and functional analysis of MET mutations in lung cancer.
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).